LARIMAR THERAPEUTICS, INC. Financing Cash Flow
LARIMAR THERAPEUTICS, INC. (LRMR) reported Financing Cash Flow of $107.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$435.00K.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $108.11M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $36.00K.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was $30.00K.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $65.09M, a 59.79% decline from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $161.88M, a 539510.00% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $30.00K, a 99.96% decline from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $75.26M, a 278.46% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $107.68M 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | $108.11M 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | $65.09M 10-K · filed 2026-03-19 | |||||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||||||
| 2024-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $66.00K derived: sum of 2 quarters · filed 2026-03-19 | -$268.00K derived: sum of 3 quarters · filed 2026-03-19 | $161.88M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$304.00K derived: sum of 2 quarters · filed 2025-08-14 | $161.85M 10-Q · filed 2024-10-30 | $161.85M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-06-30 | -$334.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $161.82M 10-Q · filed 2025-08-14 | $161.82M derived: sum of 3 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | $162.15M 10-Q · filed 2025-04-30 | $162.15M derived: sum of 2 quarters · filed 2025-04-30 | ||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $30.00K 10-K · filed 2025-03-24 | ||||||
| 2023-09-30 | $30.00K 10-Q · filed 2024-10-30 | |||||||
| 2022-12-31 | -$316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $75.26M 10-K · filed 2024-03-14 | ||||||
| 2022-09-30 | $75.57M 10-Q · filed 2023-11-14 | |||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $19.89M 10-K · filed 2023-03-14 | ||||||
| 2021-09-30 | $19.89M 10-Q · filed 2022-11-10 | |||||||
| 2020-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $107.00K derived: sum of 2 quarters · filed 2022-03-25 | $84.01M derived: sum of 3 quarters · filed 2022-03-25 | $93.59M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | -$135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $83.77M derived: sum of 2 quarters · filed 2021-11-12 | $93.34M 10-Q · filed 2021-11-12 | $96.80M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $83.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $93.48M 10-Q · filed 2021-08-12 | $96.94M derived: sum of 3 quarters · filed 2021-08-12 | $106.89M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $9.58M 10-Q · filed 2021-05-10 | -$1.81M 10-Q · filed 2020-05-07 | $13.03M derived: sum of 2 quarters · filed 2021-05-10 | $22.98M derived: sum of 3 quarters · filed 2021-05-10 | $28.88M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $13.40M derived: sum of 2 quarters · filed 2021-03-04 | $19.30M derived: sum of 3 quarters · filed 2021-03-04 | $19.39M 10-K · filed 2021-03-04 | -$5.26M 10-K · filed 2020-03-05 | |||
| 2019-09-30 | $9.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $15.85M derived: sum of 2 quarters · filed 2020-11-12 | $15.94M 10-Q · filed 2020-11-12 | -$3.50M 10-Q · filed 2019-11-06 | $17.70M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | $5.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $5.99M 10-Q · filed 2020-08-14 | -$1.72M 10-Q · filed 2019-08-08 | $7.75M derived: sum of 3 quarters · filed 2020-08-14 | $72.66M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $95.00K 10-Q · filed 2020-05-07 | $1.85M derived: sum of 2 quarters · filed 2020-05-07 | $66.76M derived: sum of 3 quarters · filed 2020-05-07 | $66.74M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $66.67M derived: sum of 2 quarters · filed 2020-03-05 | $66.65M derived: sum of 3 quarters · filed 2020-03-05 | $66.91M 10-K · filed 2020-03-05 | ||||
| 2018-09-30 | $64.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $64.89M derived: sum of 2 quarters · filed 2019-11-06 | $65.15M 10-Q · filed 2019-11-06 | $83.88M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $243.00K 10-Q · filed 2019-08-08 | $18.97M derived: sum of 3 quarters · filed 2020-03-05 | |||||
| 2018-03-31 | $261.00K 10-Q · filed 2019-05-09 | $18.99M derived: sum of 2 quarters · filed 2020-03-05 | ||||||
| 2017-12-31 | $18.73M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $16.56M 10-K · filed 2020-03-05 | ||||||
| 2017-09-30 | -$2.17M 10-Q · filed 2018-11-09 | |||||||
| 2017-06-30 | -$1.44M 10-Q · filed 2018-08-09 | |||||||
| 2016-12-31 | -$2.71M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |